Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been assigned an average recommendation of “Moderate Buy” from the sixteen research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $199.5333.

A number of brokerages have weighed in on PVLA. Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Chardan Capital reaffirmed a “buy” rating and issued a $240.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stephens reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Stifel Nicolaus set a $250.00 price target on shares of Palvella Therapeutics in a report on Tuesday, February 24th. Finally, Mizuho increased their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th.

Hedge Funds Weigh In On Palvella Therapeutics

Large investors have recently modified their holdings of the stock. Aberdeen Group plc bought a new position in shares of Palvella Therapeutics in the third quarter valued at about $3,212,000. First Light Asset Management LLC bought a new position in Palvella Therapeutics during the third quarter worth about $33,949,000. Suvretta Capital Management LLC increased its position in Palvella Therapeutics by 15.1% during the third quarter. Suvretta Capital Management LLC now owns 822,400 shares of the company’s stock worth $51,556,000 after acquiring an additional 107,937 shares during the period. Apis Capital Advisors LLC bought a new position in Palvella Therapeutics during the third quarter worth about $627,000. Finally, Fred Alger Management LLC increased its position in Palvella Therapeutics by 1,279.1% during the third quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock worth $11,707,000 after acquiring an additional 173,209 shares during the period. 40.11% of the stock is owned by institutional investors.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $112.63 on Thursday. The firm’s 50-day moving average is $118.97 and its 200-day moving average is $108.85. Palvella Therapeutics has a 52-week low of $20.20 and a 52-week high of $151.18. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -27.01 and a beta of -0.15.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.30). Equities analysts predict that Palvella Therapeutics will post -5.26 EPS for the current year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.